RxSight, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
RxSight adopted a 2026 Inducement Equity Incentive Plan on July 13, 2026 (amended September 27, 2026) authorizing 4,250,000 shares for grants to new employees as inducement compensation under Nasdaq Rule 5635(c)(4). Separately, the company entered a consulting agreement with Raymond Cohen (former board director, resigned before August 13, 2026 effective date) for transition-related advisory services through February 13, 2027, granting 12,000 RSUs vesting monthly over 6 months, subject to continued service and no material breach.
Why this rating
Plan adoption is standard boilerplate; 4.25M shares (~1.2% dilution assuming ~350M shares outstanding) is routine. Cohen consulting agreement is immaterial: 12,000 RSUs (~0.003% dilution) for transition work post-resignation.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.